Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Satya Pathi, Peter Peterson, Ryan Mangelson, Ethika Tyagi, Jason M. Foulks, Clifford J. Whatcott, David J. Bearss and Steven L. Warner
Title Abstract B080: PKM2 activation modulates metabolism and enhances immune response in solid tumor models
Journal Mol Cancer Ther
Vol 18
Issue 12 Supplement
Date December 1 2019
URL https://mct.aacrjournals.org/content/18/12_Supplement/B080
Abstract Text

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable TP-1454 + unspecified PD-1 antibody Preclinical Actionable In a preclinical study, TP-1454 combined with an anti-PD1 antibody reduced tumor growth in a syngeneic mouse model of colorectal cancer, and synergistically inhibited tumor growth in another syngeneic mouse model (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B080). detail...
Unknown unknown lung carcinoma not applicable TP-1454 Preclinical - Cell line xenograft Actionable In a preclinical study, TP-1454 treatment inhibited viability of an epithelial lung carcinoma cell line in culture, and reduced tumor growth in a cell line xenograft model (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B080). detail...
Unknown unknown colorectal cancer not applicable TP-1454 + unspecified CTLA4 antibody + unspecified PD-1 antibody Preclinical Actionable In a preclinical study, TP-1454 combined with an anti-CTLA4 and an anti-PD1 antibody inhibited tumor growth and increased survival in a syngeneic mouse model of colorectal cancer (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B080). detail...
Unknown unknown colorectal cancer not applicable TP-1454 + unspecified CTLA4 antibody Preclinical Actionable In a preclinical study, TP-1454 treatment combined with an anti-CTLA4 antibody inhibited tumor growth and increased survival in a syngeneic mouse model of colorectal cancer (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B080). detail...